Clinical Trial

Open, Non-comparative Pilot Study to Evaluate the Safety and Efficacy of Intraovarian Plasma Rich in Growth Factors (PRGF) in Patients With Low Ovarian Reserve

Recruiting

Record status

This record was last updated June 12, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.

Summary

The use of plasma rich in growth factors (PRGF) improves ovarian reserve markers and IVF laboratory parameters in women with low ovarian reserve. Primary objective To compare ovarian reserve markers and IVF-ICSI laboratory results before and after PRGF infusion. Secondary Objectives * To compare pre- and post-treatment pregnancy rates. * To collect complications associated with the application of intraovarian PRGF. General Outline of the Study VISIT 1 * Patient Selection * Confirm that he/she has all the analyses and variables to be studied. * Signing of Informed Consent * Usual IVF protocol (1st IVF cycle) VISIT 2 * Instillation of intraovarian PRGF on the day of the puncture of the 1st IVF cycle in the FJD VISIT 3 * Analytical control at 4 weeks VISIT 4 * Analytical control at 8 weeks VISIT 5 * In case of failure to achieve gestation Start of 2nd cycle of IVF

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2025-05-13; most recent amendment 2025-06-11.

Status change: Not Yet Recruiting → Recruiting 2025-06-11

Trial Details

NCT Number	NCT06975683
Lead Sponsor	Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Conditions	Low Ovarian Reserve
Enrollment	50 participants
Start Date	2025-05-30
Primary Completion	2026-05 (estimated)
Study Completion	2026-05 (estimated)
Updated on ClinicalTrials.gov	2025-06-12